title: [CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
abstract: A case of acute undifferentiated leukemia (AUL), accompanied by subcutaneous tumor and thymoma is reported. The analysis of immunophenotype showed that the leukemic blasts were positive for CD7, HLA-DR, CD38 and CD34 in 17.5% but negative results were obtained for other lymphoid and myeloid antigens. The leukemic blasts had a rearranged immunoglobulin heavy chain (IgH) gene and T cell receptor delta (TCR-delta) chain gene chromosomal abnormality, 47, XY, +8, t(13; 17) (q12; q21), -17, +M was observed. In general, the CR rate is low and prognosis is poor in patients with AUL. In our case, CR was not achieved by the therapy with JALSG-ALL87 protocol, but was achieved by subsequent treatment with high dose ara-C therapy and combination chemotherapy including intermediate-dose ara-C, mitoxantrone, etoposide and prednisolone.
authors.affiliation: Forth Department of Internal Medicine, Sapporo Medical University.
authors.forename: T
authors.initials: T
authors.lastname: Doi
authors.forename: S
authors.initials: S
authors.lastname: Sakamaki
authors.forename: K
authors.initials: K
authors.lastname: Koike
authors.forename: T
authors.initials: T
authors.lastname: Matsunaga
authors.forename: D
authors.initials: D
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Muramatsu
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Kougo
authors.forename: Y
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000208:Acute Disease; D015703:Antigens, CD; D019011:Antigens, CD7 / Q000032:analysis*; D000943:Antigens, Differentiation / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D015321:Gene Rearrangement; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D016130:Immunophenotyping; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008562:Membrane Glycoproteins; D008942:Mitoxantrone / Q000008:administration & dosage; D009699:N-Glycosyl Hydrolases / Q000032:analysis*; D011239:Prednisolone / Q000008:administration & dosage; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000235:genetics; D012074:Remission Induction; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D013945:Thymoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D013953:Thymus Neoplasms / Q000150:complications / Q000188:drug therapy / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D019011:Antigens, CD7; D000943:Antigens, Differentiation; D006684:HLA-DR Antigens; D007143:Immunoglobulin Heavy Chains; D008562:Membrane Glycoproteins; D016692:Receptors, Antigen, T-Cell, gamma-delta; D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; D008942:Mitoxantrone; D009699:N-Glycosyl Hydrolases; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1